STOCK TITAN
  1. Home
  2. News
  3. CBAY

Cymabay Therapeutics Inc - CBAY STOCK NEWS

IMPACT
SENTIMENT
CBAY : Nasdaq
CymaBay’s RESPONSE Phase 3 Data Evaluating Seladelpar for Primary Biliary Cholangitis to be Featured in an Oral Late-Breaking Presentation at The Liver Meeting® 2023
clinical trial
IMPACT
SENTIMENT
CBAY : Nasdaq
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
IMPACT
SENTIMENT
CBAY : Nasdaq
CymaBay Initiates AFFIRM, a Phase 3b/4 Study Evaluating the Effect of Seladelpar on Clinical Outcomes in Patients with Cirrhosis due to Primary Biliary Cholangitis
clinical trial
IMPACT
SENTIMENT
CBAY : Nasdaq
CymaBay Therapeutics to Present at the Cantor Global Healthcare Conference
conferences
IMPACT
SENTIMENT
CBAY : Nasdaq
CymaBay Announces Closing of Upsized $258.7 Million Public Offering of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
offering
IMPACT
SENTIMENT
CBAY : Nasdaq
CymaBay Announces Pricing of Upsized $225 Million Public Offering of Common Stock and Pre-Funded Warrants
offering
IMPACT
SENTIMENT
CBAY : Nasdaq
CymaBay Announces Proposed $150 Million Public Offering of Common Stock and Pre-Funded Warrants
offering
IMPACT
SENTIMENT
CBAY : Nasdaq
CymaBay's Seladelpar Achieves High Statistical Significance for the Primary and Key Secondary Endpoints in the Phase 3 RESPONSE Trial in Primary Biliary Cholangitis
clinical trial
IMPACT
SENTIMENT
CBAY : Nasdaq
CymaBay to Host Investor Call to Share Topline Results from the Phase 3 RESPONSE Trial of Seladelpar in Primary Biliary Cholangitis on September 7, 2023
conferences clinical trial
IMPACT
SENTIMENT
CBAY : Nasdaq
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Stock CBAY logo
Cymabay Therapeutics Inc
Nasdaq:CBAY

CBAY Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link

About CBAY

cymabay therapeutics is a clinical-stage biopharmaceutical company located in the san francisco bay area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. we are committed to developing breakthrough medicines that improve the lives of patients and their families. cymabay was seeded with the assets from an earlier metabolic disease company in which more than $120m was invested to produce a robust pipeline.